Early-phase studies on EGFR-mutant NSCLC patients suggest that these drug combinations may deepen responses in selected patients, although optimization of patient selection, treatment sequencing, and toxicity management remain key areas for future research. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.